Ironwood Pharmaceuticals

Latest news

• Ironwood Pharmaceuticals Announces FDA Approval of New Indication for Linzess (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
  12 June 2023
• FDA Approves Duzallo (lesinurad and allopurinol) for Hyperuricemia in Patients with Uncontrolled Gout
  21 August 2017
• U.S. FDA Approves 72 mcg Dose of Linzess (linaclotide) for Adults with Chronic Idiopathic Constipation
  26 January 2017
• Ironwood Announces New Drug Application for Duzallo (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review
  4 January 2017
• FDA Approves Zurampic (lesinurad) to Treat High Blood Uric Acid Levels Associated with Gout
  22 December 2015
• FDA Advisory Committee Recommends the Approval of Lesinurad for Gout Patients
  23 October 2015
• FDA Approves Linzess to Treat Certain Cases of Irritable Bowel Syndrome and Constipation
  30 August 2012
• Ironwood Announces FDA Advisory Committee Meeting Will Not Be Scheduled in Connection with New Drug Application for Linaclotide
  8 February 2012
• Ironwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA Review
  24 October 2011
• Ironwood and Forest Announce Submission of New Drug Application for Linaclotide for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation
  9 August 2011

Drugs Associated with Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.